Royalty Pharma plc (RPRX)

Basic

  • Market Cap

    $12.04B

  • EV

    $20.68B

  • Shares Out

    444.89M

  • Revenue

    $2,324.23M

  • Employees

    —

Margins

  • Gross

    59.3%

  • EBITDA

    43.74%

  • Operating

    43.56%

  • Pre-Tax

    16.03%

  • Net

    7.93%

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    7.44%

  • ROE

    15.67%

  • ROCE

    12.27%

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $47.88

  • P/E

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

Per Share

  • Rev

    $5.2

  • Earnings (Dil)

    $0.41

  • FCF

    —

  • Book Value

    $13.77

Growth (CAGR)

  • Rev 3Yr

    5%

  • Rev 5Yr

    6.96%

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    -55.59%

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    10.66%

  • EBITDA Fwd 2Yr

    -0.22%

  • EPS Fwd 2Yr

    3.21%

  • EPS LT Growth Est

    2.82%

Dividends

  • Yield

    —

  • Payout

    191.35%

  • DPS

    $0.79

  • DPS Growth 3Yr

    73.99%

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    9.37%

Select a metric from the list below to chart it

Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
LTM
Metric
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
LTM

Total Revenues

1,794.9

1,814.3

2,122.4

2,289.5

2,237.2

2,324.2

Total Revenues % Chg.

12.3%

1.1%

17.0%

7.9%

-2.3%

3.4%

Cost of Goods Sold, Total

-57.3

-1,019.3

230.8

452.8

904.2

946.0

Gross Profit

1,852.2

2,833.6

1,891.5

1,836.6

1,333.0

1,378.2

Selling General & Admin Expenses, Total

61.9

103.4

181.7

182.8

227.3

263.8

R&D Expenses

392.6

83.0

26.3

200.1

177.1

102.0

Amortization of Goodwill and Intangible Assets

33.3

23.9

23.1

23.0

5.7

—

Other Operating Expenses, Total

487.8

210.4

231.1

405.9

410.1

365.8

Operating Income

1,364.4

2,623.2

1,660.5

1,430.7

922.9

1,012.4

Interest Expense, Total

-268.0

-341.2

-168.0

-166.1

-188.0

-186.9

Interest And Investment Income

24.4

22.3

28.4

53.5

78.3

109.6

Net Interest Expenses

-243.6

-318.9

-139.6

-112.6

-109.6

-77.2

Income (Loss) On Equity Invest.

-7.0

-32.5

44.5

-19.5

-9.0

21.8

Other Non Operating Income (Expenses)

-1.5

33.9

-33.5

-27.2

81.9

-7.9

EBT, Excl. Unusual Items

1,112.3

2,305.7

1,531.8

1,271.4

886.1

949.1

Gain (Loss) On Sale Of Investments

405.5

155.7

265.7

-30.2

-40.3

39.2

Gain (Loss) On Sale Of Assets

—

—

—

—

—

—

Asset Writedown

—

—

-65.1

—

-615.8

-615.8

Other Unusual Items

—

—

-30.5

—

—

—

EBT, Incl. Unusual Items

1,517.9

2,461.4

1,702.0

1,241.2

230.1

372.5

Earnings From Continuing Operations

1,517.9

2,461.4

1,702.0

1,241.2

230.1

372.5

Minority Interest

-140.1

-112.9

-726.9

-621.5

-187.2

-188.1

Net Income

1,377.7

2,348.5

975.0

619.7

42.8

184.4

Preferred Dividend and Other Adjustments

—

—

479.8

—

—

—

Net Income to Common Incl Extra Items

1,377.7

2,348.5

495.2

619.7

42.8

184.4

Net Income to Common Excl. Extra Items

1,377.7

2,348.5

495.2

619.7

42.8

184.4

Total Shares Outstanding

36.7

—

388.1

433.0

443.2

445.8

Weighted Avg. Shares Outstanding

36.7

—

375.4

414.8

438.0

446.7

Weighted Avg. Shares Outstanding Dil

36.7

—

375.5

414.8

438.0

446.7

EPS

37.5

—

1.3

1.5

0.1

0.4

EPS Diluted

37.5

—

1.3

1.5

0.1

0.4

EBITDA

1,397.7

2,647.1

1,683.5

1,453.7

928.6

1,016.7